PK
Park Hotels & Resorts Inc.
$14.88
+0.28
(+1.92%)
Mkt Cap
3.00B
Volume
4,872,867
52W Range
9.84-14.95
Sector
Real Estate
Beta
1.33
EPS (TTM)
-1.08
P/E Ratio
-7.37
Revenue (TTM)
2.53B
Rev Growth (5Y)
+24.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$10.50
Overvalued
strong signal
41.8% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Real Estate Investment Trust
26.1 / 100 pillar composite (overridden)
A real-estate investment trust — graded A–F vs. similar companies.
Company Description
Park Hotels & Resorts Inc. operates as the second-largest publicly traded real estate investment trust (REIT) focused on the lodging sector. It manages a diversified collection of 60 premium-branded hotels and resorts, which are market leaders and possess considerable underlying real estate value. These properties include over 33,000 guest rooms, predominantly situated in prime urban centers and popular resort destinations.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.54B | 2.60B | 2.70B | 2.50B | 1.36B | 852.00M | 2.84B | 2.74B | 2.79B | 2.73B | 2.69B | 2.51B |
| Net Income | (283.00M) | 212.00M | 97.00M | 162.00M | (459.00M) | (1.44B) | 306.00M | 472.00M | 2.62B | 133.00M | 292.00M | 176.00M |
| EPS | -1.42 | 1.02 | 0.44 | 0.71 | -1.94 | -6.12 | 1.44 | 2.33 | 12.38 | 0.67 | 1.47 | 0.89 |
| Free Cash Flow | 102.00M | 202.00M | 218.00M | 241.00M | (191.00M) | (524.00M) | 259.00M | 256.00M | 468.00M | 172.00M | 293.00M | 345.00M |
| FCF / Share | 0.51 | 0.98 | 1.02 | 1.06 | -0.81 | -2.22 | 1.22 | 1.26 | 2.22 | 0.87 | 1.48 | 1.74 |
| Operating CF | 398.00M | 429.00M | 503.00M | 409.00M | (137.00M) | (438.00M) | 499.00M | 444.00M | 653.00M | 399.00M | 519.00M | 516.00M |
| Total Assets | 7.70B | 9.16B | 9.42B | 9.73B | 9.74B | 10.59B | 11.29B | 9.36B | 9.71B | 9.83B | 9.79B | 9.71B |
| Total Debt | 4.26B | 4.79B | 4.71B | 4.85B | 4.98B | 5.37B | 4.80B | 2.95B | 2.96B | 3.01B | 4.06B | 4.25B |
| Cash & Equiv | 232.00M | 402.00M | 717.00M | 906.00M | 688.00M | 951.00M | 346.00M | 410.00M | 364.00M | 293.00M | 72.00M | 42.00M |
| Book Value | 3.13B | 3.65B | 3.81B | 4.34B | 4.45B | 4.89B | 6.50B | 5.63B | 6.01B | 3.87B | 2.82B | 2.62B |
| Return on Equity | -0.09 | 0.06 | 0.03 | 0.04 | -0.10 | -0.29 | 0.05 | 0.08 | 0.44 | 0.03 | 0.10 | 0.07 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00M | 629.00M | 610.00M | 672.00M | 630.00M | 625.00M | 649.00M | 686.00M | 639.00M | 657.00M | 679.00M | 714.00M |
| Net Income | 11.00M | (205.00M) | (16.00M) | (5.00M) | (57.00M) | 66.00M | 54.00M | 64.00M | 28.00M | 187.00M | 27.00M | (150.00M) |
| EPS | 0.05 | -1.03 | -0.08 | -0.03 | -0.29 | 0.32 | 0.26 | 0.31 | 0.13 | 0.88 | 0.13 | -0.70 |
| Free Cash Flow | (24.00M) | (3.00M) | 31.00M | 65.00M | 9.00M | 17.00M | 97.00M | 66.00M | 22.00M | 51.00M | 56.00M | 76.00M |
| FCF / Share | -0.12 | -0.02 | 0.16 | 0.33 | 0.04 | 0.08 | 0.47 | 0.32 | 0.11 | 0.24 | 0.26 | 0.35 |
| Operating CF | 59.00M | 105.00M | 99.00M | 108.00M | 86.00M | 80.00M | 140.00M | 117.00M | 92.00M | 141.00M | 127.00M | 146.00M |
| Total Assets | 7.66B | 7.70B | 8.83B | 8.87B | 8.90B | 9.16B | 9.17B | 9.17B | 9.09B | 9.42B | 9.30B | 9.34B |
| Total Debt | 4.04B | 4.05B | 4.78B | 4.78B | 4.79B | 4.79B | 4.79B | 4.80B | 4.71B | 4.71B | 4.71B | 4.72B |
| Cash & Equiv | 156.00M | 232.00M | 278.00M | 319.00M | 233.00M | 402.00M | 480.00M | 449.00M | 378.00M | 717.00M | 726.00M | 797.00M |
| Book Value | 3.09B | 3.13B | 3.38B | 3.44B | 3.49B | 3.65B | 3.75B | 3.78B | 3.79B | 3.81B | 3.98B | 4.06B |
| Return on Equity | 0.00 | -0.07 | -0.00 | -0.00 | -0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.05 | 0.01 | -0.04 |
PK News
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference®
This High-Dividend Real Estate ETF Holds Some Bargains
Park Hotels & Resorts: This Rally May Not Be Over
Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
KBWY Up 20% This Year, But The Real Test Comes When Rent Rolls Reset
3 Hotel REITs Poised to Benefit from the World Cup
Park Hotels & Resorts Gets An Upgrade As It Invests In Upgrading Portfolio
Are Investors Undervaluing Park Hotels & Resorts (PK) Right Now?
Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers